الفهرس 
Multiple myeloma epidemiology
Clinical presentation, investigations and stagingOnly 14 pages are availabe for public view
 |  | from | 150 |  |  |
| | | from | 150 | | |
Abstract
Multiple myeloma is the second most common hematologic malignancy worldwide following Non Hodgkin lymphoma with an estimated 176404 new cases and an estimated 117077 deaths in 2020, both sexes, both ages, and still incurable but one of the hematologic malignancies have witnessed a new era over the last 15 years (Sung et al., 2020). Multiple myeloma is a cancer originates from plasma cell usually from bone marrow, divided into two subtypes: active or symptomatic multiple myeloma and smoldering multiple myeloma. At time of diagnosis multiple myeloma patient’s symptoms and signs are often non-specific; including general fatigue, bony pain, unintentional significant weight loss, anemia of unknown origin and accidentally discovered impaired renal functions.